摘要: Afatinib (BIBW 2992, US: Gilotrif TM , other countries: Giotrif©) is an irreversible blocker of the ErbB family, acting at the tyrosine kinases of these proteins. In 2013, it was approved by …
elsevier.com
springer.com
sci-hub.se 参考文章(151)
Nobuyuki Katakami, Shinji Atagi, Koichi Goto, Toyoaki Hida, Takeshi Horai, Akira Inoue, Yukito Ichinose, Kunihiko Koboyashi, Koji Takeda, Katsuyuki Kiura, Kazuto Nishio, Yoko Seki, Ryuichi Ebisawa, Mehdi Shahidi, Nobuyuki Yamamoto, LUX-Lung 4: A Phase II Trial of Afatinib in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed During Prior Treatment With Erlotinib, Gefitinib, or Both Journal of Clinical Oncology. ,vol. 31, pp. 3335- 3341 ,(2013) , 10.1200/JCO.2012.45.0981
James Chih-Hsin Yang, Yi-Long Wu, Martin Schuler, Martin Sebastian, Sanjay Popat, Nobuyuki Yamamoto, Caicun Zhou, Cheng-Ping Hu, Kenneth O'Byrne, Jifeng Feng, Shun Lu, Yunchao Huang, Sarayut L Geater, Kye Young Lee, Chun-Ming Tsai, Vera Gorbunova, Vera Hirsh, Jaafar Bennouna, Sergey Orlov, Tony Mok, Michael Boyer, Wu-Chou Su, Ki Hyeong Lee, Terufumi Kato, Dan Massey, Mehdi Shahidi, Victoria Zazulina, Lecia V Sequist, Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials Lancet Oncology. ,vol. 16, pp. 141- 151 ,(2015) , 10.1016/S1470-2045(14)71173-8
Jie Ting, PharmD Tien Ho, Pin Xiang, Amanda Sugay, Maher Abdel-Sattar, Leslie Wilson, Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States Value in Health. ,vol. 18, pp. 774- 782 ,(2015) , 10.1016/J.JVAL.2015.04.008
T.Y. Seiwert, J. Fayette, D. Cupissol, J.M. del Campo, P.M. Clement, R. Hitt, M. Degardin, W. Zhang, A. Blackman, E. Ehrnrooth, E.E.W. Cohen, A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck Annals of Oncology. ,vol. 25, pp. 1813- 1820 ,(2014) , 10.1093/ANNONC/MDU216
Yoshihiro Shibata, Masato Chiba, The Role of Extrahepatic Metabolism in the Pharmacokinetics of the Targeted Covalent Inhibitors Afatinib, Ibrutinib, and Neratinib Drug Metabolism and Disposition. ,vol. 43, pp. 375- 384 ,(2015) , 10.1124/DMD.114.061424
Jean-Charles Soria, Enriqueta Felip, Manuel Cobo, Shun Lu, Konstantinos Syrigos, Ki Hyeong Lee, Erdem Göker, Vassilis Georgoulias, Wei Li, Dolores Isla, Salih Z Guclu, Alessandro Morabito, Young J Min, Andrea Ardizzoni, Shirish M Gadgeel, Bushi Wang, Vikram K Chand, Glenwood D Goss, Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial The Lancet Oncology. ,vol. 16, pp. 897- 907 ,(2015) , 10.1016/S1470-2045(15)00006-6
Sanjay Popat, Tony Mok, James Chih-Hsin Yang, Yi-Long Wu, Juliane Lungershausen, Uz Stammberger, Ingolf Griebsch, Tiago Fonseca, Luis Paz-Ares, None, Afatinib in the treatment of EGFR mutation-positive NSCLC--a network meta-analysis. Lung Cancer. ,vol. 85, pp. 230- 238 ,(2014) , 10.1016/J.LUNGCAN.2014.05.007
A. Suder, J.E. Ang, F. Kyle, D. Harris, S. Rudman, R. Kristeleit, F. Solca, M. Uttenreuther-Fischer, K. Pemberton, K. Pelling, D. Schnell, J. de Bono, J. Spicer, A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours. European Journal of Cancer. ,vol. 51, pp. 2275- 2284 ,(2015) , 10.1016/J.EJCA.2015.07.041
Edurne Arriola, Noemi Reguart, Angel Artal, Manuel Cobo, Rosario García-Campelo, Emilio Esteban, Mari Carmen Rodríguez, Maria Pilar García-Muret, Management of the adverse events of afatinib: a consensus of the recommendations of the Spanish expert panel. Future Oncology. ,vol. 11, pp. 267- 277 ,(2015) , 10.2217/FON.14.214
James C-H Yang, Lecia V Sequist, Sarayut Lucien Geater, Chun-Ming Tsai, Tony Shu Kam Mok, Martin Schuler, Nobuyuki Yamamoto, Chong-Jen Yu, Sai-Hong I Ou, Caicun Zhou, Daniel Massey, Victoria Zazulina, Yi-Long Wu, Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6 The Lancet Oncology. ,vol. 16, pp. 830- 838 ,(2015) , 10.1016/S1470-2045(15)00026-1